Literature DB >> 21605943

Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies.

Gillian C Barnett1, Catharine M L West, Charlotte E Coles, Paul D P Pharoah, Christopher J Talbot, Rebecca M Elliott, George A Tanteles, R Paul Symonds, Jennifer S Wilkinson, Alison M Dunning, Neil G Burnet, Søren M Bentzen.   

Abstract

PURPOSE: The search for clinical and biologic biomarkers associated with late radiotherapy toxicity is hindered by the use of multiple and different endpoints from a variety of scoring systems, hampering comparisons across studies and pooling of data. We propose a novel metric, the Standardized Total Average Toxicity (STAT) score, to try to overcome these difficulties. METHODS AND MATERIALS: STAT scores were derived for 1010 patients from the Cambridge breast intensity-modulated radiotherapy trial and 493 women from the University Hospitals of Leicester. The sensitivity of the STAT score to detect differences between patient groups, stratified by factors known to influence late toxicity, was compared with that of individual endpoints. Analysis of residuals was used to quantify the effect of these covariates.
RESULTS: In the Cambridge cohort, STAT scores detected differences (p < 0.00005) between patients attributable to breast volume, surgical specimen weight, dosimetry, acute toxicity, radiation boost to tumor bed, postoperative infection, and smoking (p < 0.0002), with no loss of sensitivity over individual toxicity endpoints. Diabetes (p = 0.017), poor postoperative surgical cosmesis (p = 0.0036), use of chemotherapy (p = 0.0054), and increasing age (p = 0.041) were also associated with increased STAT score. When the Cambridge and Leicester datasets were combined, STAT was associated with smoking status (p < 0.00005), diabetes (p = 0.041), chemotherapy (p = 0.0008), and radiotherapy boost (p = 0.0001). STAT was independent of the toxicity scale used and was able to deal with missing data. There were correlations between residuals of the STAT score obtained using different toxicity scales (r > 0.86, p < 0.00005 for both datasets).
CONCLUSIONS: The STAT score may be used to facilitate the analysis of overall late radiation toxicity, from multiple trials or centers, in studies of possible genetic and nongenetic determinants of radiotherapy toxicity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605943     DOI: 10.1016/j.ijrobp.2011.03.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Association of XRCC1 and XRCC3 gene haplotypes with the development of radiation-induced fibrosis in patients with nasopharyngeal carcinoma.

Authors:  Isabella Wai Yin Cheuk; Shea Ping Yip; Dora Lai Wan Kwong; Vincent Wing Cheung Wu
Journal:  Mol Clin Oncol       Date:  2014-04-14

Review 2.  Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

Authors:  Sarah L Kerns; Harry Ostrer; Barry S Rosenstein
Journal:  Cancer Discov       Date:  2014-01-17       Impact factor: 39.397

Review 3.  Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity.

Authors:  Barry S Rosenstein
Journal:  Semin Radiat Oncol       Date:  2017-10       Impact factor: 5.934

4.  Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.

Authors:  Christian Nicolaj Andreassen; Barry S Rosenstein; Sarah L Kerns; Harry Ostrer; Dirk De Ruysscher; Jamie A Cesaretti; Gillian C Barnett; Alison M Dunning; Leila Dorling; Catharine M L West; Neil G Burnet; Rebecca Elliott; Charlotte Coles; Emma Hall; Laura Fachal; Ana Vega; Antonio Gómez-Caamaño; Christopher J Talbot; R Paul Symonds; Kim De Ruyck; Hubert Thierens; Piet Ost; Jenny Chang-Claude; Petra Seibold; Odilia Popanda; Marie Overgaard; David Dearnaley; Matthew R Sydes; David Azria; Christine Anne Koch; Matthew Parliament; Michael Blackshaw; Michael Sia; Maria J Fuentes-Raspall; Teresa Ramon Y Cajal; Agustin Barnadas; Danny Vesprini; Sara Gutiérrez-Enríquez; Meritxell Mollà; Orland Díez; John R Yarnold; Jens Overgaard; Søren M Bentzen; Jan Alsner
Journal:  Radiother Oncol       Date:  2016-07-18       Impact factor: 6.280

Review 5.  Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?

Authors:  Carsten Herskind; Christopher J Talbot; Sarah L Kerns; Marlon R Veldwijk; Barry S Rosenstein; Catharine M L West
Journal:  Cancer Lett       Date:  2016-03-02       Impact factor: 8.679

6.  Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity.

Authors:  Gillian C Barnett; Rebecca M Elliott; Jan Alsner; Christian N Andreassen; Osama Abdelhay; Neil G Burnet; Jenny Chang-Claude; Charlotte E Coles; Sara Gutiérrez-Enríquez; Maria J Fuentes-Raspall; Maria C Alonso-Muñoz; Sarah Kerns; Annette Raabe; R Paul Symonds; Petra Seibold; Chris J Talbot; Frederik Wenz; Jennifer Wilkinson; John Yarnold; Alison M Dunning; Barry S Rosenstein; Catharine M L West; Søren M Bentzen
Journal:  Radiother Oncol       Date:  2012-11-28       Impact factor: 6.280

7.  Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity.

Authors:  Leila Dorling; Gillian C Barnett; Kyriaki Michailidou; Charlotte E Coles; Neil G Burnet; John Yarnold; Rebecca M Elliott; Alison M Dunning; Paul D P Pharoah; Catharine M West
Journal:  Clin Cancer Res       Date:  2015-10-28       Impact factor: 12.531

8.  A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.

Authors:  Laura Fachal; Antonio Gómez-Caamaño; Gillian C Barnett; Paula Peleteiro; Ana M Carballo; Patricia Calvo-Crespo; Sarah L Kerns; Manuel Sánchez-García; Ramón Lobato-Busto; Leila Dorling; Rebecca M Elliott; David P Dearnaley; Matthew R Sydes; Emma Hall; Neil G Burnet; Ángel Carracedo; Barry S Rosenstein; Catharine M L West; Alison M Dunning; Ana Vega
Journal:  Nat Genet       Date:  2014-06-29       Impact factor: 38.330

9.  A replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy.

Authors:  C J Talbot; G A Tanteles; G C Barnett; N G Burnet; J Chang-Claude; C E Coles; S Davidson; A M Dunning; J Mills; R J S Murray; O Popanda; P Seibold; C M L West; J R Yarnold; R P Symonds
Journal:  Br J Cancer       Date:  2012-07-05       Impact factor: 7.640

10.  Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.

Authors:  Mahbubl Ahmed; Leila Dorling; Sarah Kerns; Laura Fachal; Rebecca Elliott; Matt Partliament; Barry S Rosenstein; Ana Vega; Antonio Gómez-Caamaño; Gill Barnett; David P Dearnaley; Emma Hall; Matt Sydes; Neil Burnet; Paul D P Pharoah; Ros Eeles; Catharine M L West
Journal:  Br J Cancer       Date:  2016-04-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.